Jubilant Pharmova posts consolidated Q2 FY26 PAT at Rs. 120.3 Cr

Dr Lal Path Labs reports consolidated Q2 FY26 PAT at Rs. 150.6 Cr

The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025

Indegene posts consolidated Q2 FY26 PAT at Rs. 102.1 Cr

Dr Agarwals Health Care posts consolidated Q2 FY26 PAT at Rs. 29.69 Cr

Dr Agarwals Health Care has reported total income of Rs. 506.62 crore during the period ended September 30, 2025

Dabur India reports consolidated Q2 FY26 PAT at Rs. 452.55 Cr

Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025

Dr. Agarwals Eye Hospital posts consolidated Q2 FY26 PAT at Rs. 19.32 Cr

Dr Agarwals Eye Hospital has reported total income of Rs. 118.40 crore during the period ended September 30, 2025

Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr

Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025

Indraprastha Medical Corporation posts consolidated Q2 FY26 PAT at Rs. 49.46 Cr

Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025

MedPlus Health Services posts consolidated Q2 FY26 PAT at Rs. 55.50 Cr

Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025

Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success

ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia